MARKET

HAE

HAE

Haemonetics
NYSE

Real-time Quotes | Nasdaq Last Sale

70.45
+1.48
+2.15%
After Hours: 70.45 0 0.00% 17:06 09/21 EDT
OPEN
69.35
PREV CLOSE
68.97
HIGH
70.90
LOW
67.57
VOLUME
626.76K
TURNOVER
--
52 WEEK HIGH
142.11
52 WEEK LOW
49.26
MARKET CAP
3.60B
P/E (TTM)
56.02
1D
5D
1M
3M
1Y
5Y
Why Is Haemonetics (HAE) Up 4.9% Since Last Earnings Report?
Zacks.com · 09/10 15:30
Is Haemonetics Corporation (NYSE:HAE) Worth US$64.6 Based On Its Intrinsic Value?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Haemonetics...
Simply Wall St. · 09/05 14:10
Here's Why You Should Retain Haemonetics (HAE) Stock for Now
Strong recovery across businesses and strength in plasma franchise benefited Haemonetics (HAE) during the first quarter of fiscal 2022.
Zacks · 09/01 15:33
Endurant Capital Management LP Buys Cigna Corp, Icon PLC, Thermo Fisher Scientific Inc, Sells ...
GuruFocus News · 08/27 16:38
Haemonetics Corp (HAE) EVP, CFO William P. Mr. Burke Sold $1.4 million of Shares
GuruFocus News · 08/26 01:15
Haemonetics To Present At The 19th Annual Morgan Stanley Global Healthcare Conference
/PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that , President and CEO, will present at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference on , at .
PR Newswire - PRF · 08/25 12:53
Tocqueville Asset Management L.p. Buys DuPont de Nemours Inc, eBay Inc, PACCAR Inc, Sells ...
GuruFocus News · 08/24 20:38
Royce Premier Fund's 1st-Half 2021 Manager Commentary
GuruFocus News · 08/18 20:37
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HAE. Analyze the recent business situations of Haemonetics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HAE stock price target is 79.25 with a high estimate of 90.00 and a low estimate of 68.00.
EPS
Institutional Holdings
Institutions: 432
Institutional Holdings: 55.78M
% Owned: 109.30%
Shares Outstanding: 51.03M
TypeInstitutionsShares
Increased
101
11.20M
New
53
5.41M
Decreased
77
11.29M
Sold Out
87
3.59M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.10%
Healthcare Equipment & Supplies
+0.22%
Key Executives
Non-Executive Chairman/Independent Director
Ellen Zane
President/Chief Executive Officer/Director
Christopher Simon
Chief Financial Officer/Executive Vice President
William Burke
Executive Vice President/Chief Technology Officer
Anila Lingamneni
Executive Vice President/General Counsel
Michelle Basil
Senior Vice President
Josep Llorens
Director
Lloyd Johnson
Independent Director
Robert Abernathy
Independent Director
Catherine Burzik
Independent Director
Michael Coyle
Independent Director
Charles Dockendorff
Independent Director
Mark Kroll
Independent Director
Claire Pomeroy
No Data
  • All
  • Financials
  • Insiders
More
About HAE
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

Webull offers kinds of Haemonetics Corporation stock information, including NYSE:HAE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HAE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HAE stock methods without spending real money on the virtual paper trading platform.